anti-LMO1 (LMO1) Antikörper

anti-LIM Domain Only 1 Antikörper (LMO1)
Auf finden Sie aktuell 21 LIM Domain Only 1 (LMO1) Antikörper von 4 unterschiedlichen Herstellern. Insgesamt sind aktuell 22 LMO1 Produkte verfügbar.

Meistgesuchte Reaktivitäten zu anti-LMO1 (LMO1) Antikörper

Wählen Sie die Spezies und Applikation aus

anti-Rat (Rattus) LMO1 Antikörper:

anti-Mouse (Murine) LMO1 Antikörper:

anti-Human LMO1 Antikörper:

Alle verfügbaren anti-LMO1 Antikörper

Sie gelangen zu unserer vorgefilterten Suche.

Weitere Antikörper gegen LMO1 Interaktionspartner

Mouse (Murine) LIM Domain Only 1 (LMO1) Interaktionspartner

  1. These behavioral and molecular phenotypes indicate that a genetic-driven DAT (zeige SLC6A3 Antikörper) hypofunction alters neurodevelopmental trajectories consistent with ADHD, but not with schizophrenia and bipolar disorders.

  2. An exquisite microanatomical regulation of dopamine by the dopamine transporter was identified in striosomes relative to the matrix in the corpus striatum.

  3. Data suggest that environment pollutants methylmercury and 1-methyl-4-phenylpyridinium decrease release of dopamine from dopaminergic neurons; this mechanism involves down-regulation of expression of Slc6a3 (zeige SLC6A3 Antikörper).

  4. This study show that Dopamine transporter is enriched in filopodia and induces filopodia formation.

  5. The sigma-1R deficiency through suppressing NR2B (zeige GRIN2B Antikörper) function and DAT (zeige SLC6A3 Antikörper) expression can reduce MPTP (zeige PTPN2 Antikörper)-induced death of dopaminergic neurons and parkinsonism.

  6. DAT (zeige SLC6A3 Antikörper) gene knockout in mice results dendritic spine loss in pyramidal neurons in the CA1 (zeige CA1 Antikörper) field of the hippocampus.

  7. Results show that moderate increases in DAT (zeige SLC6A3 Antikörper) function cause spontaneous dopaminergic cell loss, oxidative stress and fine motor impairment that is reversed by l-DOPA treatment

  8. Chronic and acute reductions of DAT (zeige SLC6A3 Antikörper) functioning in mice impaired decision-making.

  9. These results demonstrate that the presence of the N-terminal tag leads to impaired DAT (zeige SLC6A3 Antikörper) protein expression in vivo due in part to improper trafficking of the tagged transporter.

  10. studies demonstrate an in vivo functional impact of the DAT (zeige SLC6A3 Antikörper) Val559 variant, providing support for the ability of DAT (zeige SLC6A3 Antikörper) dysfunction to impact risk for mental illness.

Human LIM Domain Only 1 (LMO1) Interaktionspartner

  1. Allosteric modulation of human dopamine transporter activity under conditions promoting its dimerization

  2. A combined haplotype (9R-A2) of DAT-1 (zeige SLC6A3 Antikörper) and DRD2 (zeige DRD2 Antikörper) genes was associated with the murderer phenotype among Pakistani violent criminal inmates.

  3. SLC6A3 gene may have a role in susceptibility to late-onset alcohol dependence in the Han Chinese population.

  4. This result suggests that persistent drug-induced parkinsonism in patients with visually normal DAT (zeige SLC6A3 Antikörper) imaging may be associated with subtle decrement of DAT (zeige SLC6A3 Antikörper) activity.

  5. the dopamine transporter SLC6A3 constitutes a novel biomarker that is highly specific for clear cell renal cell carcinoma

  6. Data suggest that variants rs28363170 and rs3836790 in the solute carrier family 6 member 3 gene are not associated with sporadic Parkinson's disease in Han Chinese population.

  7. Study systematically designed and characterized a set of 24 substrate-based bivalent ligands, and in combination with mutagenesis, induced-fit docking calculations, electrophysiology, and cysteine accessibility measurements; revealed novel insight into the molecular basis of substrate recognition in hSERT (zeige SLC6A4 Antikörper) and hDAT

  8. these findings provide compelling experimental evidence that DAT (zeige SLC6A3 Antikörper) N and C termini synergistically contribute to substrate and inhibitor affinities.

  9. these results are the first demonstration of pharmacological chaperoning of DAT (zeige SLC6A3 Antikörper) and suggest this may be a viable approach to increase DAT (zeige SLC6A3 Antikörper) levels in Dopamine Transporter Deficiency Syndrome and other conditions associated with reduced DAT (zeige SLC6A3 Antikörper) function.

  10. total of 1799 differentially methylated regions were identified including SLC6A3, Rab40C, ZNF584, and FOXD3 whose significant methylation differences were confirmed in breast cancer patients through quantitative real-time polymerase chain reaction.Methylation of those aforementioned genes in white blood cells of our young patients may highlight their potential as early epimarkers

LMO1 Antigen-Profil

Beschreibung des Gens

This gene encodes a dopamine transporter which is a member of the sodium- and chloride-dependent neurotransmitter transporter family. The 3' UTR of this gene contains a 40 bp tandem repeat, referred to as a variable number tandem repeat or VNTR, which can be present in 3 to 11 copies. Variation in the number of repeats is associated with idiopathic epilepsy, attention-deficit hyperactivity disorder, dependence on alcohol and cocaine, susceptibility to Parkinson disease and protection against nicotine dependence.

Alternative names and synonyms associated with LMO1

  • LIM domain only 1 (Lmo1) Antikörper
  • solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 (Slc6a3) Antikörper
  • solute carrier family 6 (neurotransmitter transporter), member 3 (SLC6A3) Antikörper
  • solute carrier family 6 (neurotransmitter transporter), member 3 (Slc6a3) Antikörper
  • DAT Antikörper
  • DAT1 Antikörper
  • Lmo3 Antikörper
  • PKDYS Antikörper

Bezeichner auf Proteinebene für LMO1

LIM domain only protein 3 , LMO-3 , LIM domain only 3 , neuronal-specific transcription factor DAT1 , dopamine-inducible LIM-domain transcription factor DAT1 , DA transporter , dopamine transporter 1 , sodium-dependent dopamine transporter , solute carrier family 6 member 3 , solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 , DAT , solute carrier family 6, member 3

245979 Rattus norvegicus
13162 Mus musculus
6531 Homo sapiens
24898 Rattus norvegicus
Ausgewählte Anbieter für anti-LMO1 (LMO1) Antikörper
Haben Sie etwas anderes gesucht?